Taltz (ixekizumab) is an antibody pharmaceutical. Ixekizumab was first approved as Taltz on 2016-03-22. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. The pharmaceutical is active against interleukin-17A.
|Drug Class||Monoclonal antibodies: humanized, interleukins as target|